From 2,000+ patients · Wegovy vs Mounjaro is already seeing results
Wegovy vs Mounjaro: both are FDA-approved GLP-1 medications for weight loss. Wegovy (semaglutide) and Mounjaro (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $199/month with virtual consultations and licensed providers.
Overview
Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly) are two separate FDA-approved branded products with different active ingredients and different approved indications. Wegovy is FDA-approved for chronic weight management (2021); Mounjaro is FDA-approved for type 2 diabetes (2022). Wegovy is a GLP-1 receptor agonist; Mounjaro is a dual GIP/GLP-1 receptor agonist. Weight Method does not dispense or prescribe either brand-name product; our program provides compounded semaglutide and compounded tirzepatide through licensed providers and U.S.-licensed pharmacies. Which medication is appropriate for you is a decision made by a licensed provider based on your individual medical profile.
Key Fact
Wegovy (semaglutide) is FDA-approved for chronic weight management; Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. They are different molecules from different manufacturers with different mechanisms (single GLP-1 vs. dual GIP/GLP-1) — and both are different from Weight Method's compounded program.
Source: FDA prescribing information (Wegovy; Mounjaro)
Wegovy
Mounjaro
| Wegovy | Mounjaro | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active Ingredient | semaglutide | tirzepatide |
| FDA Indication | Chronic weight management | Type 2 diabetes |
| FDA Approval | 2021 | 2022 |
| Formulation | Injectable pen | Injectable pen |
| Frequency | Once weekly | Once weekly |
| Available Doses | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Avg. Weight Loss | 15-17% | 15-21% |
| Our Price | $199/mo | $329/mo |
Key Differences
Wegovy and Mounjaro are different molecules from different manufacturers with different FDA-approved indications (chronic weight management vs. type 2 diabetes). Wegovy acts on the GLP-1 receptor; Mounjaro acts on both the GIP and GLP-1 receptors. Which mechanism, medication, and indication is clinically appropriate for any individual depends on that person's medical history and is determined by a licensed provider, not by a general comparison. Through Weight Method, compounded semaglutide is $154/mo and compounded tirzepatide is $329/mo.
Verdict
Wegovy and Mounjaro are distinct FDA-approved branded products from different manufacturers with different approved uses; neither is what Weight Method dispenses. The right option for an individual depends on that person's medical profile and is determined by a licensed provider. Consult with your Weight Method provider to determine which compounded option aligns with your health profile.
Your Treatment Options
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.
